Alpha-Mannosidase B Deficiency

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

C
CENTOGENEGermany - Rostock
1 program
Biomarker for Mannosidosis Disease (BioMannosidosis)N/A1 trial
Active Trials
NCT03264040Withdrawn0Est. Feb 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CENTOGENEBiomarker for Mannosidosis Disease (BioMannosidosis)

Clinical Trials (1)

NCT03264040CENTOGENEBiomarker for Mannosidosis Disease (BioMannosidosis)

Biomarker for Mannosidosis Disease (BioMannosidosis)

Start: Aug 2018Est. completion: Feb 20210
N/AWithdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space